Sign In
Buy EVOK
$11.00
+0 (+0%)
At Close: Mar 16, 2026
Evoke Pharma Announces FDA Orange Book Listing of U.S. Patent for Gimoti®
08:30am, Tuesday, 08'th Jun 2021
SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced
Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray
08:30am, Thursday, 27'th May 2021
Evoke is committed to meeting patients online, where they search for answers
Evoke Pharma Appoints Vickie Reed to Board of Directors
08:30am, Friday, 14'th May 2021
SOLANA BEACH, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced t
Evoke Pharma (EVOK): Over 19% Decrease Pre-Market Explanation
07:42am, Thursday, 13'th May 2021
The stock price of Evoke Pharma Inc (NASDAQ: EVOK) fell by over 19% pre-market. This is why it happened.
Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q1 2021 Results - Earnings Call Transcript
10:42pm, Wednesday, 12'th May 2021
Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q1 2021 Results - Earnings Call Transcript
Evoke Pharma Reports First Quarter 2021 Financial Results
04:05pm, Wednesday, 12'th May 2021
Nearly 293% growth of product sales, 235% growth of prescriptions and 87% increase in new prescribers for Gimoti ®
Evoke Pharma to Report First Quarter 2021 Financial Results on May 12, 2021
08:30am, Wednesday, 05'th May 2021
SOLANA BEACH, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, tod
New patent expands intellectual property protection for nasal delivery of metoclopramide New patent expands intellectual property protection for nasal delivery of metoclopramide
Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday
11:32am, Friday, 12'th Mar 2021
Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the
Evoke Pharma, Inc. (EVOK) CEO Dave Gonyer on Q4 2020 Results - Earnings Call Transcript
10:29pm, Thursday, 11'th Mar 2021
Evoke Pharma, Inc. (EVOK) CEO Dave Gonyer on Q4 2020 Results - Earnings Call Transcript
Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
04:05pm, Thursday, 04'th Mar 2021
SOLANA BEACH, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, t
Evoke Pharma: Opportunity For Upside As Gimoti Sales Ramp
02:08am, Tuesday, 09'th Feb 2021
Evoke Pharma finally received FDA approval for Gimoti, a nasal formulation of a generic GI drug, in June 2020 and launched the drug in October 2020. Post-approval, the stock price decreased as investo
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares
08:30am, Wednesday, 20'th Jan 2021
SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, an
Evoke Pharma Announces Pricing of Public Offering of Common Stock
08:03pm, Wednesday, 13'th Jan 2021
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, to
Evoke Pharma Announces Proposed Public Offering of Common Stock
04:02pm, Wednesday, 13'th Jan 2021
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, to
